Effect of intravenous fluid supplementation in healthy term neonates with non-hemolytic hyperbilirubinemia: A randomized controlled trial

Meenakshi Sarvi, Shailesh S Patil, Arunkumar Desai

Department of Pediatrics, Belgaum Institute of Medical Sciences, Belagavi, Karnataka, India

Correspondence to: Shailesh S Patil, Department of Pediatrics, Belgaum Institute of Medical Sciences, Belagavi, Karnataka, India.
E-mail: shaileshpt@yahoo.com

Received – 19 February 2017 Initial Review – 08 March 2018 Published Online – 15 April 2018

ABSTRACT

Objective: The objective of this study was to evaluate the effect of intravenous fluid supplementation in healthy term neonates with non-hemolytic hyperbilirubinemia receiving phototherapy. Study Design: Randomized controlled trial conducted in a tertiary level neonatal care unit of a teaching institute in North Karnataka. Methods: A total of 60 healthy term neonates with non-hemolytic hyperbilirubinemia (total serum bilirubin [TSB] >15 mg/dL [256 µmol/L]–≤25 mg/dL [428 µmol/L]) were randomized to two groups. Group I (case group, n=30) received 1/3rd the maintenance intravenous fluid in addition to breastfeeding and phototherapy. Group II (control group, n=30) received only breastfeeding and phototherapy. The duration of phototherapy and rate of fall of bilirubin was compared. Results: Both the groups were comparable with respect to mean birth weight, gestational age, gender, mode of delivery, age at admission, admission weight, percentage of weight loss at admission, and TSB at inclusion. There was a significant difference in the duration of phototherapy between the two groups (mean [standard deviation (SD)] Group I, 39.6 [7.8] h and Group II, 45.2 [10.22] h, p<0.05). Percentage of fall in bilirubin was not significant at 4, 12, 48, and 60 h but was significant at 24 and 36 h. Conclusion: Intravenous fluid supplementation in healthy breastfed term neonates with non-hemolytic hyperbilirubinemia significantly reduces the duration of phototherapy.

Key words: Bilirubin, Breastfed, Duration, Phototherapy

Phototherapy is a standard treatment for neonatal jaundice. Its relative freedom from complications together with its non-invasive nature, ease of usage, and convenience has resulted in widespread acceptance in virtually all neonatal units [1]. The increase in the amount of body water loss through insensible transepidermal loss due to phototherapy along with stool water loss is commonly seen in newborn suffering from jaundice [2]. Some infants with high bilirubin level are mildly dehydrated and may need supplemental fluid to correct their dehydration. Furthermore, the photoproducts responsible for the decline in serum bilirubin are excreted in urine and bile. Hence, maintaining adequate hydration and good urine output help to improve the efficacy of phototherapy [3]. Studies done on fluid supplementation on term neonates have shown variable results [2,4,5]. Hence, this randomized control trial was conducted to evaluate whether parenteral fluid supplementation helps in reducing the duration of phototherapy in healthy term neonates with non-hemolytic hyperbilirubinemia.

MATERIALS AND METHODS

This study was conducted in a tertiary level neonatal care unit of a teaching institute in North Karnataka over a period of 12 months from December 2012 to November 2013. Healthy term neonates (≥37 weeks) weighing ≥2.5 kg at birth presenting with jaundice and total serum bilirubin (TSB) ≥15 mg/dL (256 µmol/L) from 2nd to 14th day of life were included. Written informed consent was obtained from either parent of the neonate. Ethical clearance was obtained from the institutional ethical committee.

Neonates with bilirubin encephalopathy (hypertonia, arching, retrocollis, opisthotonos, fever, and high-pitched cry) [6], TSB >25 mg/dL (428 µmol/L), conjugated bilirubin >20% of the TSB, evidence of hemolysis, signs of dehydration (weight loss >10% of birth weight, reduced skin turgor, dry mucosa, fever, and tachycardia), jaundice persisting beyond 14 days of life, sick neonates, major congenital anomalies, born to gestational diabetic mother, cephalhematoma, and neonates on intravenous fluid for any reason were excluded (Box I). Hemolysis was diagnosed if direct Coombs test was positive, peripheral blood smear showed features of hemolysis and increased reticulocyte count [7].

During the study period, 92 term neonates were admitted for jaundice, 28 neonates were excluded, and 4 parents refused to give consent (Fig. 1). Hence, 60 neonates were randomized to one of the two groups (case group n=30, control group n=30). Neonates of both the groups received exclusive breastfeeding.

Neonates were allotted using computer-generated random number, and the corresponding serial numbered was opened by an opaque, identical envelope containing group allocation to either of the
two groups. Group I (case group) received supplemental intravenous fluid along with phototherapy and breastfeeding. Group II (control group) received only phototherapy and breastfeeding.

Phototherapy was provided by special blue light phototherapy unit (Phoenix Blue CFL-tubes PL-L-18W/52/4P Chennai, Tamil Nadu). Neonates were fully exposed except for their eyes and nappy areas. Phototherapy unit was placed at a distance of 25 cm over the neonate. Phototherapy was discontinued after TSB value obtained below 15 mg/dL (256 µmol/L) (2 mg/dL (34.1 µmol/L). Neonates in case group received 1/3rd the daily maintenance fluid (80 mL/kg on day 2, 100 mL/kg on day 3, 120 mL/kg on day 4, 140 mL/kg on day 5, and 160 mL/kg on or after day 6) of 1/5th normal saline with 5% dextrose by peripheral vein till they received phototherapy.

Investigations were sent for serum bilirubin (total and direct), hemoglobin, and for evidence of hemolysis (reticulocyte count, direct Coombs test, and peripheral smear for hemolysis). Maternal blood group was obtained from mother’s records.

Neonates were periodically monitored for hydration, adequacy of feeding, signs of acute bilirubin encephalopathy, urine, and stool frequency. Daily weight was recorded. Serum bilirubin (total and direct) was repeated at 4th and 12th h and every 12 hourly by EM360 fully automated autoanalyzer using diazo method. Primary outcome measures were the duration of phototherapy and percentage of fall of TSB.

**RESULTS**

There was no significant difference with respect to birth weight, gender, weight at admission, mode of delivery, and age at admission between the two groups (Table 1). Mean (standard deviation [SD]) percentage of weight loss (case vs. control group was 5.09% [2.78] vs. 4.84% [2.2]) was not significant. Laboratory parameters (hemoglobin, reticulocyte count, and TSB at inclusion) were similar in both the groups (Table 1). Hence, factors affecting bilirubin was similar in both the groups.

There was a significant difference in the duration of phototherapy (case group 39 [7.8] h vs. control group 45.2 [10.22] h, p=0.0248). The average duration of phototherapy was shorter by 6 h in the fluid supplemented group. The percentage of fall in bilirubin at 4, 12, 48, and 60 h was not significant, but it was significant at 24 and 36 h (Table 2).

All the babies in both the groups responded to phototherapy, none of them needed exchange transfusion or developed signs of bilirubin encephalopathy. None of the neonates developed complications related to phototherapy and intravenous cannula (thrombophlebitis or evidence of sepsis).

**DISCUSSION**

Our study showed that intravenous fluid supplementation significantly reduced the duration of phototherapy in healthy term exclusively breastfed neonates presenting with non-hemolytic hyperbilirubinemia though the percentage of fall in bilirubin was not significant at all times.

The quantity of fluid supplemented differs between different studies. In one of the study, Iranpour R supplemented their study participants with 25% of the maintenance showed no benefit [2], while a study by Mehta et al. showed benefit with supplementation of 50% of daily maintenance [4]. Hence, our study was conducted to evaluate whether fluid supplementation of 1/3rd the maintenance has any benefit. We chose to give fluid by intravenous route as we believe that oral supplementation might interfere with breastfeeding, and the effectiveness of oral rehydration may not be sufficiently reliable and fast [4].

In a study done by Mehta et al. [4], benefit of fluid supplementation in term neonates presenting with severe hyperbilirubinemia was not significant at all times.

**Box I: Inclusion and exclusion criteria**

| Inclusion criteria | Exclusion criteria |
|--------------------|-------------------|
| Healthy term neonates (≥37 weeks) ≥2.5 kg at birth | Signs of bilirubin encephalopathy (hypertonia, arching, retrocollis, opisthotonos, fever, and high-pitched cry)¹⁰ |
| Presenting with jaundice from 2nd to 14th day of life | TSB>25 mg/dL (428 µmol/L) |
| Total serum bilirubin (TSB) ≥15 mg/dL (256 µmol/L) | Conjugated bilirubin>20% of the TSB |
| | Evidence of hemolysis |
| | Signs of dehydration (weight loss>10% of birth weight, reduced skin turgor, dry mucosa, fever, and tachycardia) |
| | Jaundice persisting beyond 14 days of life |
| | Sick neonates |
| | Major congenital anomalies |
| | Born to gestational diabetic mother |
| | Cephalhematoma |
| | Neonates on intravenous fluid for any other reason |

¹⁰Signs and symptoms of bilirubin encephalopathy: focal or generalized seizures; marked hypotonia or hypertonia; muscle rigidity; decorticate or decerebrate posturing; opisthotonos; fever; high-pitched cry.

**Figure 1: Patients flow diagram**
hyperbilirubinemia in the form of decreased rate of exchange transfusion and duration of phototherapy was seen. However, the case group in this study received intravenous fluid for first 8 h followed by oral supplementation with expressed breast milk or formula feeds. This study also showed the non-reliability of infants with own autoregulatory mechanisms to increase oral intake in the presence of severe hyperbilirubinemia. In a study, Saedi et al. [8] showed that additional parenteral fluid therapy in term neonates with non-hemolytic hyperbilirubinemia accelerates the reduction in serum bilirubin in first 24 h of admission. However, case group received full maintenance intravenous fluid along with breastfeeding. Boo and Lee [5] in a randomized controlled trial on severely jaundiced healthy term infants receiving intensive phototherapy showed no benefit of oral or intravenous fluid supplementation. However, the quantity of fluid given to both the groups (enteral and intravenous group) was similar, only the route of administration was different (oral vs. intravenous) and was only studied for first 4 h of phototherapy. A study by Goyal et al. [9] found no significant difference in the duration of phototherapy(3,9),(995,995)

None of the neonates of either of the groups developed features of bilirubin encephalopathy or needed an exchange transfusion. Cochrane review showed no benefit of intravenous fluid supplementation on complications related to excessive bilirubin (bilirubin encephalopathy, kernicterus, or cerebral palsy) in healthy term neonates as a risk of developing these complications was very low [10]. The American Academy of Pediatrics [3] states that there is no evidence of excessive fluid administration affecting the serum bilirubin concentration and does not recommend routine intravenous fluid, or other supplementation of the term and near-term infants receive phototherapy unless there is evidence of dehydration. However, mild dehydration may not have significant clinical signs [11]. The significance of our finding might be due to an expansion of intravascular volume leading to a slight dilutional lowering of the bilirubin, but the more important effect would be enhanced biliary flow function [4]. Cochrane review of the previous studies showed that additional fluid supplementation in healthy term neonates with unconjugated hyperbilirubinemia shortened the average duration of phototherapy by 10.7 h; however, its clinical significance was unclear [9].

The major limitation of our study was the lack of laboratory parameters to determine dehydration. However, neonates of both the groups had no clinical signs of dehydration, weight loss on admission was not significant, and the possibility of subclinical dehydration will be equally distributed between both the groups. Furthermore, complete blinding was not possible in our study. We could not rule out the glucose-6-phosphate dehydrogenase deficiency in our subjects due to non-availability of the investigation at our institution.

**CONCLUSION**

Parenteral fluid supplementation along with exclusive breastfeeding does not affect the final outcomes but helps to reduce the duration of phototherapy which will reduce the duration of hospital stay and facilitate early discharge in such neonates. Further studies comparing fluid supplementation by oral or intravenous routes with no additional fluids involving a large sample size are required to find the beneficial effect if any.

---

### Table 1: Demographic and laboratory parameters of the neonates**

| Parameter                      | Case group n=30 | Control group n=30 |
|-------------------------------|-----------------|---------------------|
| Male n (%)                    | 19 (63)         | 16 (53)             |
| Birth weight in kg            | 3.02 (0.32)     | 3.07 (0.34)         |
| Admission weight (kg)         | 2.87 (0.31)     | 2.92 (0.33)         |
| Weight loss (%)               | 5.09 (2.78)     | 4.84 (2.2)          |
| Mode of delivery n (%)        |                 |                     |
| Vaginal                       | 11 (36.6)       | 11 (36.6)           |
| Cesarean                      | 14 (46.6)       | 17 (56.6)           |
| Instrumental                  | 5 (16.6)        | 2 (6.6)             |
| Age at admission (days)       | 5.17 (2.07)     | 5.07 (1.78)         |
| Hemoglobin (g/dL)             | 15.83 (1.4)     | 15.61 (1.39)        |
| Reticulocyte count (%)        | 1.61 (0.39)     | 1.43 (0.76)         |
| TSB (mg/dL) at inclusion      | 17.35 (1.45)    | 16.11 (0.04)        |

*Results expressed as mean (SD), all P=0.05 between both groups. SD: Standard deviation, TSB: Total serum bilirubin

### Table 2: Percentage of fall in TSB and duration of phototherapy

| Time (h) | n | Case group | % of fall in TSB | Control group | % of fall in TSB | p value |
|----------|---|------------|------------------|---------------|------------------|---------|
| 4        | 30| 1.42 (0.75)|                  | 30            | 1.22 (1.42)      | 0.506   |
| 12       | 30| 6 (3.26)   |                  | 30            | 4.63 (5.84)      | 0.266   |
| 24       | 30| 11.06 (5.16)|                | 30            | 6.85 (6.28)      | 0.006*  |
| 36       | 29| 17.32 (6.86)|                | 29            | 11.36 (7.54)     | 0.002*  |
| 48       | 8 | 23.89 (9.11)|                | 16            | 19.02 (9.55)     | 0.06*   |
| 60       | 2 | 26.47 (8.14)|                | 8             | 21.87 (9.44)     | 0.30    |
| Total duration of phototherapy (h) | 39.6 (7.8) | 45.2 (10.22) | 0.0248* |

Results expressed as mean (SD). *Significant P<0.05. TSB: Total serum bilirubin, SD: Standard deviation

% of fall in TSB = \[
\frac{\text{TSB (at inclusion - at specified time)}}{\text{TSB at inclusion}} \times 100
\]
ACKNOWLEDGMENT

Dr S D Kalsad, Director BIMS, Belagavi, for permission to publish this study.

REFERENCES

1. Tan KL. Phototherapy for neonatal jaundice. Clin Perinatal 1991;18:423-39.
2. Iranpour R, Nokekhan R, Haghshenas I. Effect of intravenous fluid supplementation on serum bilirubin level in jaundiced healthy neonates during conventional phototherapy. J Res Med Sci 2004;4:186-90.
3. American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Clinical practice guideline: Management of hyperbilirubinemia in newborn infant 35 or more weeks of gestation. Pediatrics 2004;114:297-316.
4. Mehta S, Kumar P, Narang A. A randomized controlled trial of fluid supplementation in term neonates with severe hyperbilirubinemia. J Pediatr 2005;147:781-5.
5. Boo NY, Lee HT. Randomized controlled trial of oral versus intravenous fluid supplementation on serum bilirubin level during phototherapy of term infants with severe hyperbilirubinemia. J Pediatr Child Health 2002;38:151-5.
6. Volpe JJ. Neurology of the Newborn. 5th ed. Philadelphia: Saunders Elsevier; 2008. p. 619-51.
7. Gallagher GP. The Neonatal Erythrocyte and its Disorders. In: Orkin SH, Fisher DE, Ginsbury D, Look AT, Lux SE, Nathan DG, editors. Nathan and Oski’sHematology and Oncology of Infancy and Childhood. 8th ed. Philadelphia: Elsevier Saunders; 2015. p. 52-75.
8. Saedi R, Heydarian F, Fakhrizadeh M. Role of intravenous fluid therapy in icteric neonates receiving phototherapy. Saudi Med J 2009;30:1176-9.
9. Shah SU, Mehta A, Kaur J, Jain S, Guglani V, Chawla D. Fluid supplementation in management of neonatal hyperbilirubinemia. A randomized controlled trial. J Matern Fetal Neonatal Med 2017;20:1-7.
10. Lai M, Ahmed A, Choo M, Kong U, Ngim F. Fluid supplementation for neonatal unconjugated hyperbilirubinemia. Cochr Database Syst Rev 2017;8:CD0011891.
11. Duggan C, Refat M, Hashem M, Wolff M, Fayad I, Santosham M, et al. How valid are clinical signs of dehydration in infants? J Pediatr Gastroenterol Nutr 1996;22:56-61.

Funding: None; Conflict of Interest: None Stated.

How to cite this article: Sarvi M, Patil SS, Desai A. Effect of intravenous fluid supplementation in healthy term neonates with non-hemolytic hyperbilirubinemia: A randomized controlled trial. Indian J Child Health. 2018; 5(3):204-207.